A US biotech firm has opened an office in the Philippines (US biotech Philippines)
July 23, 2022
InterVenn Biosciences, a biotech firm based in the United States, has opened a cutting-edge office in the Philippines (US biotech Philippines) to capitalize on the country’s available talent.
While the company is headquartered in San Francisco’s Bay Area, OInVenn Biosciences Philippines opened its state-of-the
US biotech Philippines office is located in Ortigas Center in Pasig on Friday, emphasizing that the team that maintains its artificial intelligence (AI) is mostly made up of Filipinos residing in the Philippines.
“Thanks to the brilliant and dedicated Filipino engineers we have on board, InterVenn has made significant progress in early cancer detection,” InterVenn co-founder and CEO Aldo Carrascoso said.
“They help build and maintain the front end, back end, and cloud infrastructure of our next-generation liquid biopsy, as we all work together to make sure no one is ever caught off guard by disease,” Carrascoso added.
InterVenn has created a powerful AI-enabled software platform capable of performing glycoproteomic analysis and working on a wide range of mass spectrometry instruments to create high-throughput, automated analysis solutions for both research and clinical applications.
The platform identifies patient-specific cancer biomarkers and employs them in the development of liquid biopsy tests that can detect cancer and predict how well each patient will respond to available treatments.
The company stated that its US biotech Philippines office would continue to grow its roster of developers and engineers who serve as the backbone of the proprietary AI technology used in the firm’s research.
Over 100 Filipinos are currently working on InterVenn’s software engineering stream, with plans to hire more local talent as the company expands its operations in the region.
“All of our software is proudly made in the Philippines.” “We started this venture with the goal of demonstrating to everyone that we Filipinos can achieve this on a global scale, not just finding a cure and early detection for cancer,” InterVenn Philippines general manager Axel Kornerup said.
Kornerup also stated that the company has worked with local oncologists to run its InterVenn Ovarian Cancer Liquid Biopsy (VOCAL) testing program.
The biotech firm said it has been aggressive in its recruitment and expansion in the country to support the development and commercialization of its Dawn product, a blood-based test aimed at helping physicians appropriately match cancer patients to the best immuno-oncology therapy.
It also stated that the product’s use on other types of tumors is being researched. This is one of the services that the US biotech Philippines will offer.
“Our research is a significant step toward truly universal healthcare.” “We’re excited to be working with more local stakeholders in the future,” Carrascoso said.
Kornerup stated that the Philippine office, located at the Podium West Tower, employs approximately 150 people.
“However, we are on hold. We were supposed to hire more people, but due to the global market situation, we are temporarily putting that on hold. “We expect to increase personnel as things settle down and the market becomes more stable,” Kornerup said.
While the US biotech Philippines office has a capacity of 250 employees, Kornerup believes it could expand to 400 due to scheduling.
